Zoetis executive representatives highlight growth opportunities in India
Zoetis is a leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, bio devices and a range of services.
nox app player download
Clint Lewis, Juan Ramon Alaix and Anne-France Quentric Melay
Zoetis executives comprising Juan Ramon Alaix, CEO and Clint Lewis, Executive VP and President International Operations had recently interacted with a panel of Indian media to discuss animal health growth opportunities and strategy in the country. “As global leader in animal health, we are fully dedicated to serving the real world needs of livestock farmers and veterinarians. In doing so, we are guided by a successful business model based on our three interconnected capabilities—Our Direct Customer Relationship, Our Innovation Capability and Our High Quality Products,” said Juan Ramon. He added that Zoetis’ competitive advantage begins with the company’s singular focus on animal health.
Zoetis colleagues make the difference
Pankaj Lohan and Y Hari Prasad
“I am very proud of our Zoetis company culture that is guided by our Core Beliefs. Our colleagues drive our success. We have instilled a highly collaborative culture where colleagues demonstrate a sense of ownership. They take satisfaction from seeing the impact of their achievements on the success of our company, our customers and their businesses,” mentioned Juan Ramon.
Zoetis is investing in companion animal business, bringing innovative products into its portfolio that addresses the most pressing challenges of veterinarians. Dermatology has been an area with unmet needs and attractive opportunities for innovation – especially to treat allergic skin conditions in dogs.
“We have been able to bring innovative new products to the market and expand their access in a growing number of markets in companion animals (Apoquel, Cytopoint, Stronghold Plus, Simparica),” said Juan Ramon. Zoetis’ recent launch of Apoquel across the world and Cytopoint in the US, Europe and Canada, are promising new therapeutic solutions for veterinarians and pet parents to control the clinical signs of allergic skin conditions in dogs, such as itching. “With our Simparica, a new chewable medication to control fleas and ticks in dogs, we are already seeing success competing in the $4.2 billion market for companion animal parasiticides,” announced Juan Ramon.
India is an important market to Zoetis
“I know our colleagues in India play a big role and very proud of the way this team has adjusted to the new organisation model and embraced many significant changes to drive efficiency and growth,” said Juan Ramon. Today, Zoetis is much better positioned for sustainable growth towards 2020 with the right colleagues, focused on the right markets. India is an important part of the company’s future growth given the population, demographics and animal health needs in the country.
Zoetis is also investing in diagnostics solutions that will help producers prevent or treat diseases and use medicines properly. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
Click here to add your own text